On November 4, 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, reported that it will host a virtual key opinion leader ("KOL") event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will feature expert oncologists Eileen M. O’Reilly, MD, FASCO and Kevin C. Soares, MD, both of Memorial Sloan Kettering Cancer Center ("MSKCC"), who will join the Company’s management to discuss:
The unmet need and current treatment landscape for metastatic pancreatic ductal adenocarcinoma ("PDAC")
Camupepimut (ELI-002 7P), Elicio’s investigational Amphiphile ("AMP")-powered immunotherapy targeting common KRAS mutations
Key Phase 2 findings informing camupepimut’s late-stage development strategy
Opportunities to expand camupepimut into neoadjuvant PDAC, including the design and progress of the ongoing MSKCC-led Phase 1 trial funded by The Lustgarten Foundation and Break Through Cancer
A live question and answer session will follow the formal presentations.
About Eileen M. O’Reilly, MD, FASCO
Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at MSKCC. She serves as the Section Head for Hepatopancreaticobiliary/Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director Medical at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSKCC and Professor of Medicine at Weill Cornell Medical College.
Dr. O’Reilly is a clinical scientist whose research focus involves integration of molecular, genetic-based (RAS, BRCA, other) and immunotherapy for pancreas cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students. Dr. O’Reilly is the Principal Investigator of multiple phase I, II, III trials in pancreas cancer. She is a Clarivate highly cited author in clinical medicine. She serves as an Associate Editor for the Journal of Clinical Oncology and Senior Editor for several AACR (Free AACR Whitepaper) journals and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO"), American Association forCancer Research ("AACR"), National Institutes of Health ("NIH"), Department of Defense ("DOD"), and various international entities. She is Principal Investigator of the MSK P50 Pancreas Specialized Program of Research Excellence ("SPORE"), a National Cancer Institute ("NCI") funded team science grant. Dr. O’Reilly is the recipient of named lectureships and numerous awards including the Burkitt Medal (Trinity College Dublin) in 2022, Giants of Cancer Care (GI Oncology) in 2023 and the Whitman Award for Clinical Excellence in 2025, Exceptional Women in Medicine (2019- present) and Castle Connolly Top Doctors (2005- present).
Dr. O’Reilly’s other roles include Chair of the Human Research Protection Program and Institutional Review & Privacy Board ("IRB"). Nationally, Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves in leadership roles in several advocacy organizations including the National Pancreas Foundation, Hirshberg Foundation, PanKind and Pancreatic Cancer Action Network.
About Kevin C. Soares, MD
Dr. Kevin C. Soares obtained his undergraduate degree at Brandeis University and MD from the University of Massachusetts Medical School. He completed general surgery residency at The Johns Hopkins University School of Medicine. He completed a three-year research fellowship in cancer immunology in the Jaffee Laboratory at the Sidney Kimmel Comprehensive Cancer Center atThe Johns Hopkins University School of Medicine. After finishing residency, he completed a two-year dual fellowship in complex surgical oncology and hepatopancreatobiliary ("HPB") surgery at MSKCC. He was then appointed to the faculty of the HPB Service at MSKCC and completed a Master of Science in clinical and translational cancer research at the Louis V. Gerstner Jr. Graduate School of Biomedical Sciences,MSKCC.
Dr. Soares is a surgical oncologist and physician scientist who specializes in caring for patients with HPB malignancies. His primary research interest is combinatorial immunotherapy approaches in HPB malignancies with a particular focus on vaccine-based therapies.
About the AMPLIFY-7P Phase 2 Study
AMPLIFY-7P is a randomized Phase 2 study evaluating camupepimut (ELI-002 7P) versus observation in patients with mKRAS-driven PDAC following completion of standard therapy. The study enrolled 144 patients across 24 U.S. clinical sites.
While the study did not meet its pre-specified primary disease-free survival ("DFS") endpoint in the intent-to-treat population, subsequent analyses have provided important insights into the clinical and biological activity of camupepimut and informed the Company’s continued evaluation of the program.
At ESMO (Free ESMO Whitepaper) Congress 2026, Elicio will present new pre-specified analyses from AMPLIFY-7P that provide additional insights into the potential clinical benefit ofcamupepimut and are expected to further inform the Company’s refined Phase 3 development strategy in adjuvant pancreatic cancer.
About camupepimut (ELI-002 7P)
Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio’s proprietary AMP technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.
(Press release, Elicio Therapeutics, NOV 4, 2026, View Source [SID1234674202])